Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 8OTHER 5NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 213Carcinoma, Non-Small-Cell Lung 148Lung Neoplasms 128Lymphoma 119Prostatic Neoplasms 115Leukemia 102Ovarian Neoplasms 100Central Nervous System Neoplasms 95Precursor Cell Lymphoblastic Leukemia-Lymphoma 89Colorectal Neoplasms 89Head and Neck Neoplasms 87Sarcoma 84Multiple Myeloma 80Squamous Cell Carcinoma of Head and Neck 73Rectal Neoplasms 62Leukemia, Myeloid, Acute 62Carcinoma, Ovarian Epithelial 61Uterine Cervical Neoplasms 60Neoplasm Metastasis 59Brain Neoplasms 57Colonic Neoplasms 56Fallopian Tube Neoplasms 53Astrocytoma 53Lymphoma, Large B-Cell, Diffuse 50Glioblastoma 49Burkitt Lymphoma 47Urinary Bladder Neoplasms 46Neuroblastoma 44Melanoma 44Hodgkin Disease 44

Interventions

Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Interventional × Urothelial Cancer × Clear all
NCT02033993 2023-08-22

Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.

Canadian Cancer Trials Group

Phase 2 Completed
199 enrolled 14 charts
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡